Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment-Reference-Cited by-同舟云学术

Good tolerability of maintenance temozolomide in glioblastoma patients after severe hematological toxicity during concomitant radiotherapy and temozolomide treatment

Published:2018-10 Issue:9 Volume:29 Page:924-928
ISSN:0959-4973
Container-title:Anti-Cancer Drugs
language:en
Short-container-title:

Author:

Lombardi Giuseppe,Caccese Mario,Bellu Luisa,Pambuku Ardi,Bergo Eleonora,Berti Franco,Gardiman Marina P.,Della Puppa Alessandro,Denaro Luca,Dal Pos Sandro,Zagonel Vittorina

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Pharmacology (medical),Pharmacology,Oncology

Reference20 articles.

1. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma;Stupp;N Engl J Med,2005

2. MGMT gene silencing and benefit from temozolomide in glioblastoma;Hegi;N Engl J Med,2005

3. Temozolomide-related idiosyncratic and other uncommon toxicities: a systematic review;Dixit;Anticancer Drugs,2012

4. Clinical and genetic factors associated with severe hematological toxicity in glioblastoma patients during radiation plus temozolomide treatment: a prospective study;Lombardi;Am J Clin Oncol,2015

5. The impact of thrombocytopenia from temozolomide and radiation in newly diagnosed adults with high-grade gliomas;Gerber;Neuro Oncol,2007

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology);Journal of Neurology;2021-02-20

2. Temozolomide;Reactions Weekly;2018-11